NanoMedTrix is developing the first commercially available multi-modal contrast agents for both research and clinical markets. These game changing particles combine traditional contrast agents with nanotechnology to provide brighter images and extended imaging opportunities. This industry is large, growing, and driven by significantly high margins. The company is less than one year from the production and sale of contrast agents for the preclinical research market, with the long-term goal of expanding to the clinical market. NanoMedTrix is seeking a licensing or commercial partner to bring its innovative line of agents to the clinical market.